Skip to content

Study · Not a test of the peptide alone · 2022

5 results

ODP313 Glucagon-Stimulated Copeptin Measurements in the Differential Diagnosis of Diabetes Insipidus: A Double-Blind Randomized Placebo-Controlled Study

The source lists no authors.

Journal of the Endocrine Society1 Nov 2022

PMCIDPMC9625639 (opens in a new tab)PepBankPUB-99014451
Read at sourceSource pageAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Glucagon.

  1. 01HumanNot a test of Glucagon aloneRandomized controlled trialActivity measurement

    In healthy participants, median copeptin increases were 7.56 pmol/l with glucagon and 0.10 pmol/l with placebo, with a difference of 7.67 pmol/l.

    In plain wordsIn healthy participants, glucagon increased copeptin compared with placebo.

    Peptide
    Glucagon
    Outcome
    IncreaseCopeptin response in healthy participants
    Study

    n = 22

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Diagnostic Testing · Endocrine and hormones

    Measurements

    Median copeptin increase
    7.56 pmol/l
    glucagon, healthy; IQR 2.38-28.03
    Median copeptin change
    0.1 pmol/l
    placebo, healthy; IQR -0.70-0.68
    Copeptin difference
    7.67 pmol/l
    glucagon vs placebo; 1.98-27.09

    Source sentences

    Summary
    In healthy participants, glucagon injection stimulated copeptin with a median (IQR) increase of 7.56 (2.38; 28. 03) pmol/l, while placebo had no effect (0.10pmol/l (-0.70; 0.68); difference: 7.67 (1.98, 27. 09) pmol/l, p < 0. 001).
    2 context sentences
    Summary · context
    In this double-blind, randomized, placebo-controlled trial, we enrolled 22 healthy participants, 10 patients with central diabetes insipidus and 10 patients with primary polydipsia at the University Hospital Basel.
    Summary · context
    Each participant underwent the glucagon test, i. e., subcutaneous injection of 1mg glucagon, and placebo test, i. e., subcutaneous injection of 1 ml 0.9% sodium.

    In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Glucagon.

  2. 02HumanNot a test of Glucagon aloneRandomized controlled trialActivity measurement

    Glucagon-stimulated copeptin at a 4.6 pmol/l cutoff distinguished diabetes insipidus from primary polydipsia with 100% sensitivity (95%CI 100-100).

    In plain wordsThe glucagon-stimulated copeptin test had high sensitivity for distinguishing diabetes insipidus from primary polydipsia.

    Peptide
    Glucagon
    Outcome
    Not applicableDiagnostic sensitivity
    Study

    n: not reported in source

    Outcome group
    Diagnostic Testing · Endocrine and hormones

    Measurements

    Sensitivity
    100%
    copeptin cutoff 4.6 pmol/l; 95%CI 100-100

    Source sentences

    Summary
    Using a copeptin cutoff level of 4.6pmol/l had a sensitivity of 100% (95%CI 100-100) and a specificity of 90% (95%CI 70-100) to discriminate between diabetes insipidus and primary polydipsia.
    2 context sentences
    Summary · context
    In this double-blind, randomized, placebo-controlled trial, we enrolled 22 healthy participants, 10 patients with central diabetes insipidus and 10 patients with primary polydipsia at the University Hospital Basel.
    Summary · context
    Each participant underwent the glucagon test, i. e., subcutaneous injection of 1mg glucagon, and placebo test, i. e., subcutaneous injection of 1 ml 0.9% sodium.

    In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Glucagon.

  3. 03HumanNot a test of Glucagon aloneRandomized controlled trialActivity measurement

    Glucagon-stimulated copeptin at a 4.6 pmol/l cutoff distinguished diabetes insipidus from primary polydipsia with 90% specificity (95%CI 70-100).

    In plain wordsThe glucagon-stimulated copeptin test had high specificity for distinguishing diabetes insipidus from primary polydipsia.

    Peptide
    Glucagon
    Outcome
    Not applicableDiagnostic specificity
    Study

    n: not reported in source

    Outcome group
    Diagnostic Testing · Endocrine and hormones

    Measurements

    Specificity
    90%
    copeptin cutoff 4.6 pmol/l; 95%CI 70-100

    Source sentences

    Summary
    Using a copeptin cutoff level of 4.6pmol/l had a sensitivity of 100% (95%CI 100-100) and a specificity of 90% (95%CI 70-100) to discriminate between diabetes insipidus and primary polydipsia.
    2 context sentences
    Summary · context
    In this double-blind, randomized, placebo-controlled trial, we enrolled 22 healthy participants, 10 patients with central diabetes insipidus and 10 patients with primary polydipsia at the University Hospital Basel.
    Summary · context
    Each participant underwent the glucagon test, i. e., subcutaneous injection of 1mg glucagon, and placebo test, i. e., subcutaneous injection of 1 ml 0.9% sodium.

    In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Glucagon.

  4. 04HumanNot a test of Glucagon aloneNon-randomized trialActivity measurement

    In central diabetes insipidus, glucagon produced no relevant copeptin increase, with an increase of 0.55 pmol/l (0.21; 1.65).

    In plain wordsIn patients with central diabetes insipidus, glucagon produced no relevant copeptin increase.

    Peptide
    Glucagon
    Outcome
    No significant changeCopeptin response in central diabetes insipidus
    Study

    n = 10

    Comparator
    Baseline
    Outcome group
    Diagnostic Testing · Endocrine and hormones

    Measurements

    Median copeptin increase
    0.55 pmol/l
    glucagon, central diabetes insipidus; IQR 0.21-1.65

    Source sentences

    Summary
    In patients with central diabetes insipidus, copeptin showed no relevant increase after glucagon injection, with an increase of 0.55pmol/l (0.21; 1.65), whereas copeptin was stimulated in patients with primary polydipsia with an increase of 15.70 (5.99; 24.39) pmol/l.
    2 context sentences
    Summary · context
    In this double-blind, randomized, placebo-controlled trial, we enrolled 22 healthy participants, 10 patients with central diabetes insipidus and 10 patients with primary polydipsia at the University Hospital Basel.
    Summary · context
    Each participant underwent the glucagon test, i. e., subcutaneous injection of 1mg glucagon, and placebo test, i. e., subcutaneous injection of 1 ml 0.9% sodium.

    In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Glucagon.

  5. 05HumanNot a test of Glucagon aloneNon-randomized trialActivity measurement

    In primary polydipsia, glucagon increased copeptin by 15.70 (5.99; 24.39) pmol/l.

    In plain wordsIn patients with primary polydipsia, glucagon increased copeptin.

    Peptide
    Glucagon
    Outcome
    IncreaseCopeptin response in primary polydipsia
    Study

    n = 10

    Comparator
    Baseline
    Outcome group
    Diagnostic Testing · Endocrine and hormones

    Measurements

    Median copeptin increase
    15.7 pmol/l
    glucagon, primary polydipsia; IQR 5.99-24.39

    Source sentences

    Summary
    In patients with central diabetes insipidus, copeptin showed no relevant increase after glucagon injection, with an increase of 0.55pmol/l (0.21; 1.65), whereas copeptin was stimulated in patients with primary polydipsia with an increase of 15.70 (5.99; 24.39) pmol/l.
    2 context sentences
    Summary · context
    In this double-blind, randomized, placebo-controlled trial, we enrolled 22 healthy participants, 10 patients with central diabetes insipidus and 10 patients with primary polydipsia at the University Hospital Basel.
    Summary · context
    Each participant underwent the glucagon test, i. e., subcutaneous injection of 1mg glucagon, and placebo test, i. e., subcutaneous injection of 1 ml 0.9% sodium.

    In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Glucagon.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.